Business Context and Reporting Period
Company: Revvity, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary expectations for the fourth quarter ended December 28, 2025, and full year 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice that preliminary expectations were announced and that detailed financial results will be released on February 2, 2026.
Material Changes
No specific material changes or comparative financial data are detailed in this filing. The report indicates that the Company has issued a press release (Exhibit 99.1) containing an update on financial performance, but the specific figures are not embedded in the text of this 8-K.
Guidance, Outlook, and Management Commentary
- Earnings Release: The Company will release fourth quarter and full year 2025 financial results on February 2, 2026.
- Management Presentation: Dr. Prahlad Singh, President and CEO, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
- Disclosure Status: The information in this filing, including the press release and presentation materials, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific preliminary financial expectations for Q4 and full year 2025.
- Monitor the earnings call scheduled for February 2, 2026, for detailed results.
- Review Exhibit 99.2 for the presentation materials from the J.P. Morgan Healthcare Conference on January 13, 2026.
- Verify the trading status of Common Stock (RVTY) and 1.875% Notes due 2026 (RVTY 26) on the NYSE.